IDEXX Laboratories Inc IDXX

Morningstar Rating
$547.71 −4.51 (0.82%)
View Full Chart

Company Report

Idexx Launch of InVue Provides Path to Recurring Revenue

Idexx Laboratories has steadily increased its scale and reach in the veterinary diagnostic lab business to dig a wide moat. It is well-positioned to benefit from two key trends. First, pet ownership has grown, offering a secular tailwind since the late 1980s. Moreover, pet owners have generally demonstrated greater willingness to spend more on their animals, having more than tripled spending on pet products and services since 1994.

Price vs Fair Value

IDXX is trading at a LOCK|t?&R@# premium.
Price
$552.46
Fair Value
LOCK|NN
Uncertainty
LOCK|?!x<^
1-Star Price
LOCK|d.!S
5-Star Price
LOCK|@Z
Economic Moat
LOCK|BX
Capital Allocation
LOCK|rt<WD^?

Bulls Say, Bears Say

Bulls

Unlike human healthcare, pet health services and products require cash payments—thereby bypassing the reimbursement issues and pricing pressure associated with third-party payers.

Bears

International sales account for a substantial chunk of Idexx's total revenue; as the US dollar strengthens, Idexx would feel the pain on its top and bottom lines.

News

Articles & Videos

Trading Information

Previous Close Price
$552.46
Day Range
$547.11557.46
52-Week Range
$519.08769.28
Bid/Ask
$547.69 / $548.39
Shares Outstanding
78.88M
Market Cap
$43.24B
Volume/Avg
114,531 / 657,065

Key Statistics

Price/Earnings (Normalized)
42.79
Price/Sales
10.01
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
2.68%

Company Profile

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
11,000

Competitors

Valuation

Metric
IDXX
ZTS
ELAN
Price/Earnings (Normalized)
42.7911.6526.00
Price/Book Value
28.249.801.96
Price/Sales
10.013.472.59
Price/Cash Flow
30.3510.0125.18
Price/Earnings
IDXX
ZTS
ELAN

Financial Strength

Metric
IDXX
ZTS
ELAN
Quick Ratio
0.691.680.95
Current Ratio
1.123.152.16
Interest Coverage
36.1214.940.17
Quick Ratio
IDXX
ZTS
ELAN

Profitability

Metric
IDXX
ZTS
ELAN
Return on Assets (Normalized)
34.34%19.04%3.69%
Return on Equity (Normalized)
75.31%65.55%7.49%
Return on Invested Capital (Normalized)
44.73%24.10%6.35%
Return on Assets
IDXX
ZTS
ELAN

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|nCL%hyNYLOCK|P%$195B
Danaher Corp
DHR
LOCK|F>CtJ<$YLOCK|%!$$126B
Agilent Technologies Inc
A
LOCK|&hp&>h@LOCK|S?d$38B
Waters Corp
WAT
LOCK|!F@^gm?LOCK|@PJ$36B
IQVIA Holdings Inc
IQV
LOCK|<@^R#K%LOCK|dShV$34B
Illumina Inc
ILMN
LOCK|%Kh?NjLOCK|>jT><$29B
Mettler-Toledo International Inc
MTD
LOCK|Nggdl?#LOCK|#fKJ$26B
Labcorp Holdings Inc
LH
LOCK|x@y>h?#NLOCK|>T#cV$23B
Quest Diagnostics Inc
DGX
LOCK|zX%R&WLOCK|?n@v>$23B

Sponsor Center